RABAC1

RABAC1 (PRA1/Yip3) is a polytopic, four-transmembrane integral membrane protein whose hydrophilic N-terminus, inter-domain linker, and C-terminus all face the cytoplasm (PMID:11535589), and whose best-characterized role is to control the membrane association of Rab GTPases during vesicular trafficking. Acting catalytically as a GDI-displacement factor (GDF), purified RABAC1 dissociates prenylated Rab–GDI complexes and delivers Rab GTPases onto target membranes (PMID:14574414, PMID:16473601); it also opposes GDI-mediated extraction of membrane-bound Rab3A and binds Rab3A in a manner mutually exclusive with the SNARE VAMP2 (PMID:10751420). Its subcellular distribution is governed by an N-terminal di-arginine motif and a membrane-proximal FFAT-like motif that retain a subpopulation at ER–mitochondria contact sites, with loss of these motifs redirecting the protein toward the cell surface (PMID:33259547). Beyond Rab handling, RABAC1 serves as a trafficking adaptor and signaling modulator: it is required for Golgi trafficking of the EBV oncoprotein LMP1 and for LMP1-induced NF-κB activation (PMID:16917502), binds β-catenin to block its nuclear translocation and inhibit TCF/β-catenin transcription (PMID:16930546), and engages anti-apoptotic Bcl-2-family proteins BHRF1 and BCL2A1 to reduce their anti-apoptotic activity and promote caspase-3-dependent apoptosis (PMID:11373297, PMID:31003775). Consistent with its trafficking role, RABAC1 depletion alters cell morphology, increases motility, and causes intracellular cholesterol accumulation (PMID:20592422).

1. 1999 Low

   Establishing that RABAC1 physically engages multiple Rab GTPases defined it as a candidate Rab-pathway regulator rather than an isolated trafficking protein.

   Evidence Yeast two-hybrid screen of human brain cDNA plus fractionation of overexpressed protein

   PMID:10329441

   Open questions at the time

   • Yeast two-hybrid only, no biochemical confirmation of direct binding
   • Functional consequence of each Rab interaction not defined
   • Cytosol/membrane partitioning mechanism unresolved
2. 2000 Medium

   Showing that PRA1 opposes GDI-mediated extraction of Rab3A and competes with VAMP2 reframed it as a regulator of the Rab membrane-cycling/SNARE interface.

   Evidence Subcellular fractionation, in vitro competition/binding assays, and deletion mutagenesis

   PMID:10751420

   Open questions at the time

   • Whether GDI opposition reflects catalytic GDF activity not yet established here
   • Physiological significance of VAMP2 displacement untested in vivo
   • C-terminal control of solubility mechanistically unexplained
3. 2001 High

   Mapping the membrane topology established the structural framework for how cytosolic domains can engage Rabs and binding partners.

   Evidence N-linked glycosylation scanning and TM-substitution mutagenesis in cells and microsomes

   PMID:11535589

   Open questions at the time

   • No high-resolution structure
   • How cytosolic domains coordinate Rab vs partner binding unknown
4. 2001 Medium

   Identifying BHRF1 binding and reduction of its anti-apoptotic activity linked RABAC1 to apoptotic control via viral Bcl-2 homologs.

   Evidence Yeast two-hybrid, GST pulldown, reciprocal Co-IP, domain mapping, and viability assays

   PMID:11373297

   Open questions at the time

   • Mechanism by which binding lowers anti-apoptotic activity unclear
   • Selectivity for BHRF1 over Bcl-2 unexplained
   • Single lab
5. 2003 High

   In vitro reconstitution with purified protein settled the central mechanistic question by demonstrating catalytic GDF activity that dissociates Rab–GDI complexes and delivers Rabs to membranes.

   Evidence Biochemical reconstitution with purified Yip3/PRA1 and an in vitro GDF assay

   PMID:14574414 PMID:16473601

   Open questions at the time

   • Rab substrate specificity in cells not fully defined
   • Structural basis of GDI displacement unknown
   • Regulation of GDF activity in vivo unaddressed
6. 2003 Medium

   Demonstrating rotavirus VP4 binding via a domain shared with Rab5 binding showed pathogens exploit the RABAC1 Rab interface during infection.

   Evidence Yeast two-hybrid plus Co-IP from infected and transfected cells with VP4 domain mapping

   PMID:12768023

   Open questions at the time

   • Functional role in the viral life cycle not established
   • Whether VP4 and Rab5 compete for RABAC1 untested
   • Single lab
7. 2006 High

   Defining RABAC1 as required for LMP1 Golgi trafficking and NF-κB activation revealed a trafficking-adaptor role coupling cargo localization to signaling output.

   Evidence Reciprocal Co-IP, confocal imaging with nocodazole/BFA, RNAi, export mutant, and NF-κB reporter assays

   PMID:16917502

   Open questions at the time

   • Whether GDF/Rab activity is needed for LMP1 trafficking not separated
   • Generality to other Golgi-targeted cargo unknown
8. 2006 Medium

   Showing β-catenin binding and inhibition of TCF signaling extended RABAC1's reach into Wnt-pathway transcriptional control.

   Evidence Co-IP, confocal microscopy, TOPflash reporter, mutagenesis, and siRNA with nuclear fractionation

   PMID:16930546

   Open questions at the time

   • Mechanism blocking β-catenin nuclear entry undefined
   • Relationship to membrane/Rab function unclear
   • Single lab
9. 2010 Medium

   Linking PRA1 depletion to increased motility and cholesterol accumulation connected its trafficking function to lipid homeostasis and migration phenotypes.

   Evidence Stable knockdown clones, quantitative LC-MS proteomics, cholesterol staining, and rescue experiments

   PMID:20592422

   Open questions at the time

   • Direct molecular link from Rab/GDF activity to cholesterol transport unproven
   • Effector proteins driving migration not validated individually
10. 2012 Medium

    Identifying NDRG2 as a partner that synergizes in downregulating TCF activity placed RABAC1 in a cooperative module of Wnt suppression.

    Evidence Yeast two-hybrid, GST pulldown, Co-IP, TCF reporter, and GSK3β phosphorylation immunoblot

    PMID:23068607

    Open questions at the time

    • Biochemical basis of synergy with NDRG2 unknown
    • Connection to GSK3β regulation mechanistically unresolved
11. 2019 Medium

    Showing BCL2A1 binding with induction of caspase-3 and reduced proliferation/invasion reinforced a pro-apoptotic, anti-tumor role through Bcl-2-family inhibition.

    Evidence GST pulldown, Co-IP, caspase-3 activity, clonogenic and migration/invasion assays in gastric cancer cells

    PMID:31003775

    Open questions at the time

    • Mechanism of BCL2A1 inhibition undefined
    • In vivo tumor relevance not tested
    • Single lab
12. 2020 Medium

    Identifying an ER–mitochondria contact-site pool and dual N-terminal retention motifs explained how RABAC1 steady-state localization is controlled.

    Evidence Co-localization with ER/mitochondria markers, retention-motif mutagenesis, and surface-expression flow cytometry

    PMID:33259547

    Open questions at the time

    • Function at contact sites unknown
    • FFAT-like motif partner (e.g., VAP) not identified
    • Relationship of localization to GDF activity untested
13. 2024 Medium

    Yeast Yip3 was shown to negatively regulate COPII transport by hindering Sec16 assembly, positioning the ortholog as an ER lipid-sensing effector of anterograde transport.

    Evidence Genetic epistasis in the Ino2/Ino4 pathway with Sec16 assembly and Sar1 activation assays (preprint)

    Open questions at the time

    • Preprint, single lab, not peer-reviewed
    • Whether human RABAC1 regulates COPII similarly untested
    • Mechanism of Sec16 inhibition not at molecular detail

• How the catalytic GDF activity is mechanistically integrated with RABAC1's diverse non-Rab partners (β-catenin, Bcl-2 family, LMP1) and its contact-site localization remains unresolved.
• No structure of RABAC1 alone or with Rab/GDI
• Unclear whether signaling roles depend on or are independent of GDF activity
• Physiological Rab substrate repertoire in human cells undefined